TrovaGene (NASDAQ:TROV) & Adaptimmune Therapeutics (NASDAQ:ADAP) Head to Head Analysis
TrovaGene (NASDAQ:TROV) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares TrovaGene and Adaptimmune Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adaptimmune Therapeutics||$59.51 million||6.07||-$95.51 million||($0.96)||-3.59|
This is a summary of recent ratings and recommmendations for TrovaGene and Adaptimmune Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TrovaGene presently has a consensus target price of $15.50, suggesting a potential upside of 620.93%. Adaptimmune Therapeutics has a consensus target price of $7.03, suggesting a potential upside of 103.62%. Given TrovaGene’s stronger consensus rating and higher possible upside, equities analysts clearly believe TrovaGene is more favorable than Adaptimmune Therapeutics.
Institutional and Insider Ownership
6.0% of TrovaGene shares are held by institutional investors. Comparatively, 66.3% of Adaptimmune Therapeutics shares are held by institutional investors. 2.0% of TrovaGene shares are held by insiders. Comparatively, 22.4% of Adaptimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk & Volatility
TrovaGene has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
This table compares TrovaGene and Adaptimmune Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Adaptimmune Therapeutics beats TrovaGene on 9 of the 14 factors compared between the two stocks.
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.